March 2026 Quarterly Activities Report & Appendix 4C
Filed with ASX · · 10 pages · English
Summary by 6ix AI
Additionally, Avecho has secured a commercial partnership with Sandoz AG for the Australian market, which includes milestone payments and royalties upon commercialization. The financial update indicates a cash balance at the end of the quarter and outlines the company's ongoing investments in research and development activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Avecho completes recruitment for Phase III interim analysis
- Annual Report 31 December 2025
- December 2025 Quarterly Activities Report & Appendix 4C
- Phase III CBD Clinical Trial Recruitment Update
- AVE Secures US & EU Patent Allowances for CBD Soft-Gel
Later from Avecho Biotechnology
- Expiry of Listed Options
- Avecho completes treatment for Phase III interim analysis
- Receipt of Research & Development Tax Incentive
- Positive interim results from Phase III insomnia program
- Positive interim analysis advances Avecho Phase III insomnia program
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology